Elsevier launches EmBiology to deliver the unparalleled insights into biological activities that accelerate drug discovery

Elsevier, a leader in global information analytics, has launched EmBiology, a research tool that visualizes a comprehensive landscape of biological relationships, empowering researchers to gain a rapid understanding of disease biology and focus on critical evidence. Like Elsevier’s medical research database Embase, EmBiology extracts and delivers information from Elsevier content and third-party publishers. Powered by Elsevier’s Biology Knowledge Graph, EmBiology draws on more than 7.2 million full-text journal articles, 34.5 million abstracts and 430,000 clinical trials. Researchers working in drug discovery and development will be able to intuitively explore biological relationships and concepts to improve drug target and biomarker identification and prioritization. The depth and reliability of EmBiology’s data will enable more confident decision making about what targets to pursue and how to modulate the disease process.

“Researchers at pharmaceutical companies are faced with the monumental task to uncover insights from overwhelming amounts of information to identify new, more effective therapies. Intense competition demands that insights are identified quickly and confidently; researchers need to be equipped with data skills to do that,” comments Dr. Sherry Winter, Director of Biology and Biomedical Solutions at Elsevier. “EmBiology relieves this pressure by collating critical disease data into a single place and structuring it in an interactive way. This facilitates evidence-based research decisions for successful projects that ultimately bring novel treatments to patients faster.”

EmBiology surfaces relationship information, including directionality and effect, for a wide range of subject areas including expression, biomarkers and regulation. Elsevier automates data curation with technology that transforms unstructured text into structured information. The resulting knowledge graph includes 1.4 million entities connected by 15.7 million relationships to enable deep insights from a broad range of literature, with more added weekly, so researchers can be confident they are always viewing the latest concepts and terms. Results are displayed in a Sankey diagram that visually facilitates understanding of disease development, progression and drug responsiveness, whatever the researchers’ level of data skills. Users can also apply filters to narrow down their research questions and rapidly confirm their experimental hypotheses for new drug targets, biomarkers and drug repurposing projects.

“Elsevier has a longstanding reputation as a leader in managing and disseminating scientific information and classifying life science data,” continues Dr. Winter. “A team of subject matter experts developed and refined our Biology Knowledge Graph over a period of more than 20 years. EmBiology is built on this powerful data model, so that researchers can get precise answers to their questions without worrying about structuring data.”

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.